Top News
EHR Data Could Be Used to Establish a Clinicogenomic Database
AFP SPEAR T-Cells Deemed Safe in First 2 Treated Patients With Hepatocellular Carcinoma
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
Less Postoperative Chemotherapy for Pediatric Hepatoblastoma Has No Effect on Disease Control
Clinical Photography Enhances Tumor Assessment Documentation
CDC Clarifies Position on Use of Opioids in Patients With Cancer
Nanatinostat Gets Orphan Drug Designation for EBV-Associated Cancers
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
CAR-T Therapy Active in Malignant Pleural Mesothelioma
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts. -
Claims-Based Survival Models Have Potential to Aid Prostate Cancer Decision Making
“Most men with early-stage prostate cancer will die with their disease, not from their disease,” Dr Murphy said. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Immunosuppression Tied to Poor Outcomes in Multiple Cutaneous SCC
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma. -
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen. -
Types of Drugs Used to Treat Cancer
This fact sheet provides an overview of several major types of anticancer treatments.
More Features
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
The Hidden Privilege of Reference Genomes
Researchers establish a Chinese-specific BRCA database to cover nearly all of the BRCA variation information currently known across this population.
Understanding the Limitations of CAR-T Cell Therapies
CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.
Digital Issue
